SCYX News and Press, SCYNEXIS Inc. From 06/21/23

2023-06-21 12:15:22 ET New Jersey-based biotech Scynexis ( NASDAQ: SCYX ) announced Wednesday that it achieved a performance-based milestone payment worth $25M from its partner GSK ( NYSE: GSK ) over its studies into antifungal agent ibrexafungerp. The payment comes afte...

JERSEY CITY, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the achievement of a $25 million performance-based development mile...

JERSEY CITY, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that David Angulo, President and Chief Executive Officer, will take...

2023-05-21 04:41:46 ET Summary With their first product approval last quarter, Europe should follow suit. Their U.S. partner is experienced in commercializing antibiotics. Their second drug candidate is likely to succeed in Phase 2. Cidara Therapeutics ( CDTX ) i...

2023-05-19 16:57:45 ET Summary SCYX's 1Q23 earnings highlights steadily underwhelming ibrexafungerp sales, with substantial growth expected in 2024/2025 once GSK begins promotion. Phase 3 MARIO trial data, pivotal for potential label expansion, is anticipated in 1H'24. The study f...

Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens. Antimicrobial resistant C. auris is becoming a major public health threat and is found in over 3...

SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of up to $503 million and tiered royalties. GSK obtains the exclusive rights to ibrexafungerp; SCYNEXIS retains rights to all other assets in its proprietary class of enfumafungin-derived ...

2023-05-11 07:47:50 ET SCYNEXIS press release ( NASDAQ: SCYX ): Q1 GAAP EPS of -$0.71. Revenue of $1.13M (+63.8% Y/Y). For further details see: SCYNEXIS GAAP EPS of -$0.71, revenue of $1.13M

SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME ® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment from GSK of $90 million upon deal close with future performance-based milestone...

2023-04-24 09:13:55 ET Cidara Therapeutics ( NASDAQ: CDTX ) announced Monday that it received a $20M milestone payment from its partner Melinta Therapeutics ( OTCPK:MLNTQ ) following the FDA approval of candidemia treatment Rezzayo last month. The U.S. approved the once we...